Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | CDC25B | P30305 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.36 |
| ▸ | APAF1 | O14727 | 3/20 | 0.36 |
| ▸ | TDP2 | O95551 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | GALK1 | P51570 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | S100A4 | P26447 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | PTPRC | P08575 | 2/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | TERT | O14746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.36 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6646609 | 0.71 | MEN1 (0.38) | MEN1KMT2ACDC25BMAOAAPAF1 | |
| SCHEMBL3043881 | 0.71 | — | — | |
| SCHEMBL7834812 | 0.68 | MAOA (0.37) | MEN1KMT2ACDC25BMAOAAPAF1 | |
| SCHEMBL10974212 | 0.64 | GSK3B (0.37) | MEN1KMT2ACDC25BMAOAAPAF1 | |
| SCHEMBL624689 | 0.63 | MEN1 (0.39) | MEN1KMT2ACDC25BMAOAAPAF1 | |
| SCHEMBL1920482 | 0.62 | NOS3 (0.39) | MEN1KMT2AMAOAMAPTNPC1 | |
| SCHEMBL2095985 | 0.62 | KMT2A (0.50) | MEN1KMT2ACDC25BMAOAAPAF1 | |
| SCHEMBL22474210 | 0.62 | HRH4 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7921203 | 0.62 | — | — | |
| SCHEMBL1750489 | 0.62 | MEN1 (0.58) | MEN1KMT2ACDC25BMAOAAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 919 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023036177-A1 | THIOPHENE RING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 中国科学院分子细胞科学卓越创新中心 | 2023-03-16 | — | — | WO | claimed |
| EP-3927705-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| EP-3927706-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF PROLIFERATIVE DISORDERS | 1st Biotherapeutics, Inc. (KR) | 2021-12-29 | — | — | EP | claimed |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2021-11-11 | — | — | US | claimed |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | claimed |
| CN-111315727-A | Benzothiazole compounds and methods of using the same for treating neurodegenerative diseases | 第一生物治疗股份有限公司 | 2020-06-19 | — | — | CN | claimed |
| EP-2049502-B1 | 2,4-SUBSTITUTED QUINAZOLINES AS LIPID KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-04 | — | — | EP | claimed |
| US-7795271-B2 | Substituted pyrimidinones | PHARMACIA CORPORATION (US) | 2010-09-14 | — | — | US | claimed |
| EP-1620395-B1 | AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDERS | VERNALIS RES LTD (GB) | 2009-12-30 | — | — | EP | claimed |
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | PFIZER INC | 2009-12-10 | — | — | US | claimed |
| WO-1997049674-A1 | MATRIX METALLOPROTEINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-12-31 | — | — | WO | claimed |
| WO-1996027595-A1 | HETEROCYCLYCARBOXAMIDES AND OTHER COMPOUNDS FOR THE TREATMENT OF THE CARDIAC ARRHYTHMIAS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-09-12 | — | — | WO | claimed |
| EP-0719263-A1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-07-03 | — | — | EP | claimed |
| EP-0710236-A1 | AZALICYCLOOCTANE DERIVATIVES AS ANTI-ARRHYTHMIC AGENTS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-05-08 | — | — | EP | claimed |
| EP-0700389-A1 | ANTI-ARRHYTHMIC N-SUBSTITUTED 3-BENZAZEPINES OR ISOQUINOLINES | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-03-13 | — | — | EP | claimed |
| EP-0700385-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1996-03-13 | — | — | EP | claimed |
| WO-1995007903-A1 | HETEROCYCLIC CARBOXAMIDE DERIVATIVES WITH ANTIARRHYTHMIC ACTIVITY | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1995-03-23 | — | — | WO | claimed |
| WO-1995003301-A1 | AZALICYCLOOCTANE DERIVATIVES AS ANTI-ARRHYTHMIC AGENTS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1995-02-02 | — | — | WO | claimed |
| WO-1994027971-A1 | ANTI-ARRHYTHMIC N-SUBSTITUTED 3-BENZAZEPINES OR ISOQUINOLINES | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1994-12-08 | — | — | WO | claimed |
| WO-1994027967-A1 | NOVEL COMPOUNDS | SMITHKLINE BEECHAM LABORATOIRES PHARMACEUTIQUES (FR) | 1994-12-08 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306108-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | MEN1 3915/4885KMT2A 3940/4885CDC25B 463/4885 |
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | MEN1 3004/4885KMT2A 2106/4885CDC25B 3959/4885 |
| US-20210347774-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | MEN1 3004/4885KMT2A 2106/4885CDC25B 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.